Healthcare Industry News: Kyphoplasty
News Release - September 21, 2009
Medtronic, Inc. Launches Innovative Cement Delivery System for KYPHON(R) Balloon KyphoplastyKYPHON(R) Cement Delivery System Offers Out of Fluoroscopic Field Delivery and the Ability to Halt Bone Cement Flow On Demand
MINNEAPOLIS--(HSMN NewsFeed)--Medtronic, Inc. (NYSE:MDT ), today announced the full U.S. launch of the KYPHON Cement Delivery System (CDS), adding an innovative bone cement delivery option to its extensive KYPHON Balloon Kyphoplasty product portfolio for the treatment of vertebral compression fractures (VCFs).
“With the CDS device, we are expanding the options for controlled delivery of bone cement into the vertebral body,” said Alex DiNello, vice president and general manager, KYPHON(R) products, part of the Spinal and Biologics business at Medtronic. “As balloon Kyphoplasty is adopted by more and more physicians as the treatment of choice for vertebral compression fractures, we will continue to deliver products, such as the CDS, that are designed with clinician safety in mind.”
“The CDS is another innovative product from Medtronic that increases physician safety by decreasing the radiation exposure exponentially,” said Dr. Thomas Andreshak, an orthopaedic surgeon with St. Vincent Hospital in Maumee, Ohio.
During the minimally invasive balloon Kyphoplasty procedure, a needle and tube are used to create a small pathway into the fractured bone, generally on both sides of the vertebral body. Orthopedic balloons are inserted and then inflated inside the fractured bone in an attempt to raise the height of the collapsed vertebra and return it to its normal height. Inflation of the balloons creates cavities in the vertebral body that are filled with bone cement, forming an “internal cast” to support the surrounding bone and prevent further collapse.
Balloon Kyphoplasty differs from other surgical therapies for VCFs such as vertebroplasty, which is designed to stabilize the fracture without correcting vertebral body deformity or providing a controlled fill for bone cement distribution. With balloon Kyphoplasty, inflation of the balloons compacts the cancellous bone, which may fill fracture lines and reduce leak pathways. The presence of the space also allows a more viscous bone cement to be injected under low manual pressure. These features are designed to potentially reduce the risk of leakage.
Medtronic has treated more than 700,000 fractures worldwide with balloon Kyphoplasty and has trained approximately 14,000 spine specialists worldwide to perform balloon Kyphoplasty.
Medtronic will introduce the KYPHON Cement Delivery System at the annual meeting of the Congress of Neurological Surgeons (CNS) in October and at the North American Spine (NASS) meeting in November.
More information about the KYPHON Cement Delivery System can be found at www.kyphon.com.
About Medtronic’s Spinal and Biologics Business
The Spinal and Biologics business is based in Memphis, Tenn. It is the global leader in today’s spine market and is committed to advancing the treatment of spinal conditions. The Spinal and Biologics business works with world-renowned surgeons, researchers and innovative partners to offer state-of-the-art products and technologies for neurological, orthopedic, dental, and spinal conditions. Information about treatment therapies can be found at these patient-education Web sites: www.spinalfracture.com, www.xstop.com, www.back.com, www.iscoliosis.com, www.maturespine.com and www.necksurgery.com.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 24, 2009. Actual results may differ materially from anticipated results.
KYPHON Balloon Kyphoplasty incorporates technology developed by Gary K. Michelson, M.D.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.